Zelira Therapeutics (AU:ZLD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zelira Therapeutics is gearing up to present its latest business advancements at the Automic Invest 2024 conference, highlighting its successful proprietary cannabinoid medications like HOPE® and ZENIVOL®. With a robust pipeline and strategic partnerships, Zelira is expanding its market presence in the US, Australia, and Germany, aiming for significant growth in the global cannabinoid-based medicine sector.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
